索凡替尼临床合理用药中国多学科专家共识(2024版)  

Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice(2024 edition)

作　　者：索凡替尼临床合理用药中国多学科专家共识编审小组 徐建明 沈琳[3] 依荷芭丽·迟 谭煌英[5] 宋丽杰[6] 吴胤瑛 Chinese Multidisciplinary Expert Consensus on the Rational Use of Surufatinib in Clinical Practice-Editorial Board Group;Xu Jianming;Shen Lin(不详;Department of Medical Oncology,The Fifth Medical Center,General Hospital of the People's Liberation Army,Beijing 100071,China;Department of Gastrointestinal Oncology,Peking University Cancer Hospital and Institute,Beijing 100142,China)

机构地区：[1]不详 [2]解放军总医院第五医学中心肿瘤内科,北京100071 [3]北京大学肿瘤医院消化肿瘤内科,北京100142 [4]国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院、北京协和医学院肿瘤医院内科 [5]中日友好医院中西医结合肿瘤内科 [6]郑州大学第一附属医院肿瘤内科 [7]西安交通大学第一附属医院肿瘤内科

出　　处：《中华肿瘤杂志》2024年第10期930-939,共10页Chinese Journal of Oncology

摘　　要：神经内分泌肿瘤是一组起源于神经内分泌系统的异质性肿瘤,可发生于身体的任何部位,以肺以及胃肠胰神经内分泌肿瘤较为常见。近年来,全球神经内分泌肿瘤的发病率相较于其他类型肿瘤上升趋势更为显著,尤其是在近40年间(1973—2018年)神经内分泌肿瘤的发病率明显升高。神经内分泌肿瘤的药物治疗手段包括生长抑素类似物药物、抗血管生成靶向药物、核素治疗和化疗等。索凡替尼是靶向血管内皮生长因子受体1~3、成纤维细胞生长因子受体1和集落刺激因子1受体的口服酪氨酸激酶受体抑制剂。基于索凡替尼治疗非胰腺神经内分泌肿瘤和胰腺神经内分泌肿瘤的2项研究结果,2020年和2021年索凡替尼获得国家药品监督管理局批准上市,用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好(G1、G2)的非胰腺和胰腺来源的神经内分泌瘤,目前针对索凡替尼治疗其他瘤种的探索性研究正在进行。在索凡替尼治疗期间,常见的不良反应包括高血压、蛋白尿、出血、肝脏实验室检查异常以及腹泻。为了临床上更加合理、有效使用索凡替尼,国内相关领域的多学科专家根据索凡替尼上市前后的临床实践,参考其他抗血管生成抑制剂的使用经验,经过共同讨论和反复修改,最终形成《索凡替尼临床合理用药中国多学科专家共识(2024版)》,以供临床医师参考。Neuroendocrine neoplasms are a group of heterogeneous tumors originating from the neuroendocrine system,which can occur in any part of the body.Pulmonary and gastroenteropancreatic neuroendocrine tumors are the most common.In recent years,the global incidence of neuroendocrine tumors has increased more significantly than other types of tumors,especially in the past 40 years.The drug treatment of neuroendocrine tumors includes somatostatin analogues,anti-angiogenesis targeting drugs,nuclide therapy and chemotherapy.Surufatinib is an oral tyrosine kinase receptor inhibitors that targets for vascular endothelial growth factor receptor(VEGFR1-3),fibroblast growth factor receptor 1(FGFR1),and colony-stimulating factor-1 receptor(CSF-1R),has received approval in 2020 and 2021 for the treatment of locally advanced or metastatic,progressive nonfunctional,well-differentiated(G1,G2)neuroendocrine tumors(NETs)of both pancreatic and extrapancreatic origin that are unresectable.Ongoing exploratory studies are investigating its potential application in other tumor types.Common adverse reactions observed during surufatinib treatment include hypertension,proteinuria,bleeding events,and hepatic lab test abnormal and diarrhea.Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice(2024 edition)aims to provide standardized guidance for its rational use and enhance patient compliance to maximize therapeutic benefits.

关 键 词：神经内分泌肿瘤 索凡替尼 不良反应 

分 类 号：R979.1[医药卫生—药品]